INTRODUCTION
The existence of a pituitary hormone required for normal growth has been recognized since the beginning of this Received for publication 24 July 1974 and in revised form 30 August 1974.
century (1) (2) (3) . However it was not until 1944 that the isolation and partial purification of a growth-stimulating factor from sheep pituitaries was effected (4) . Growth hormone is unique among the peptide hormones in showing marked species specificity in its biologic action (5) . The ineffectiveness in man of animal growth hormones has been shown to arise from distinct chemical differences between the hormone from primates and from lower species (6, 7) . Marked species specificity is also manifest in the radioimmunoassay system, porcine and bovine growth hormones being less than 1/10,000 as immunoreactive as primate growth hormone with the antihuman growth hormone antiserum prepared in our laboratory (8) and widely distributed by the Hormone Distribution Officer of the National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, Md.
Before the development of radioimmunoassay methodology, it was not possible to measure growth hormone in normal human blood. However evidence had accumulated that the action of growth hormone on skeletal tissue is mediated by a substance whose concentration in plasma is growth hormone dependent. This factor was originally called "sulfation factor" (SF)1 because it stimulates the uptake of radioactive sulfate in the costal cartilage of hypophysectomized rats (9) . It has been shown to decrease in human and rat plasma after hypophysectomy and to increase after the administration of human growth hormone to hypophysectomized patients or beef growth hormone to hypophysectomized rats (9, 10) . Since the original reports (9, 10) , the existence of SF has been amply confirmed, and evidence has been accumulating suggesting additional properties for growth hormone (GH) -dependent serum factor(s). A more general designation, "somatomedin," has been introduced (11) , which is used as a generic term for any GH-dependent substance that appears to mediate the action of GH or somatotropin. Although GH shows marked species specificity both with respect to its biologic and immunologic properties, there has until now been no evidence for similar species specificity of any of the somatomedins.
Recently at least three somatomedins with differences in chemical and biologic properties have been described (12, 13) ; Somatomedin A which stimulates sulfate uptake by chick cartilage (14, 15) ; Somatomedin B which stimulates DNA synthesis in human glia-like cells (16) ;
and Somatomedin C, a peptide more basic than somatomedin A or B and which stimulates sulfate uptake in rat cartilage (13) . In the present report we describe the development of a radioimmunoassay for purified Somatomedin B and its application to some biochemical and clinical studies. The advantages of radioimmunoassay, namely its simplicity, sensitivity, and specificity, make feasible the investigation of a host of chemical procedures and physiologic effects in numbers that would be prohibitive with the use of more tedious bioassays.
METHODS

Radioimmunoassay
Preparation of antisera. Approximately 25 mg of KABI luman purified Somatomedin B2 (preparation I) was provided for immunization. Conjugation to guinea pig albumin (fraction V) was effected using the carbodiimide method of Goodfriend, Levine, and Fasman (17) with only minor variations. Six guinea pigs were immunized with the coupled preparation containing 0.2-0.5 mg of Somatomedin B homogenized in complete Freund's adjuvant according to the usual procedures of our laboratory (18) . Antibody was detectable in the sera from all animals. However serum from only one animal was useful for radioimmunoassay at dilutions up to 1: 4,000 (antiserum 101) and from another at 1: 500 (antiserum 105). To conserve antigen, only these two animals received more than four immunizing doses. The major portion of all bleedings of guinea pig 101 with similar titer was pooled and used for the studies reported here.
Preparation of radioiodine-labeled somatomedin: Somatomedin B preparations (I, II, and III) were labeled with radioiodine using the chloramine-T technique with only minor variations (18) . Specific activity of the labeled preparations ranged from 10 to 50 ,ACi radioiodine/,g of mate-2 Three different Somatomedin B preparations were obtained from AB KABI Research Department. Preparation I was purified from human plasma by Cohn fractionation, acid ethanol extraction, and gel chromatography (12) . Preparation II was similar. Preparation III had been further purified by electrophoresis and contained no Somatomedin A activity according to bioassay performed by Dr. Kerstin Hall.
rial. Generally '5I-labeled preparations were used for radioimmunoassay, and "3'I-labeled preparations were employed for studies of the distribution and metabolism of somatomedin in dogs. Purification (18) of iodination mixtures was effected either by Sephadex G-50 gel filtration or by starch gel electrophoresis using the method of Smithies (19) . Generally, the eluates from starch gel were more suitable for radioimmunoassay. For most studies the less pure preparation II was used for labeling since contaminants were removed by the starch gel purification. More than 50% of the total labeled peptide could be bound in antibody excess. Using the best eluate from starch gel, generally more than 90% was bindable to antibody. Thus approximately 40% of the labeled material that did not bind to antibody was removed by starch gel purification. No differences were observed between labeled Somatomedin B II or III after purification, and these preparations were used interchangeably.
Standards. Preparation III (Som B III), which was presumed to be the most highly purified Somatomedin B preparation made available to us, was used as standard, and all concentrations are expressed in terms of immunoreactivity equivalent to a known weight of Som B III per milliliter.
Experimental conditions used for assay. The standard diluent for the assay is 4% control guinea pig serum in 0.02 M barbital buffer (pH 8.6). Antiserum 101 is used at a final dilution up to 1: 4,000. 4-6 days of incubation at 40C are required to reach equilibrium at this dilution. The volume of the incubation mixture is 0.5 ml. Separation is effected with 0.1 ml of uncoated charcoal (50 mg/ml 0.02-M barbital buffer). The double antibody method of separation of bound from free-labeled hormone can also be employed. To minimize the amount of second antibody required in these assays the standard diluent has a lower concentration of control guinea pig plasma, i.e., 1% control guinea pig plasma in the same barbital buffer.
Immunoreactive Somatomedin B in human plasma was determined in a dilution of 1: 20,000 or greater and in monkey plasma in a dilution of 1: 5,000 or greater. Plasma from other species including guinea pig, mouse, rat, cow, dog, sheep, pig, or rabbit was assayed at a 1: 20 dilution. Somatomedin B content of several of the plasma protein fractions prepared by the Cohn method was also determined. These fractions were a gift of the Protein Foundation, Boston, Mass. They were obtained as a dry powder and were soluble at a concentration of 1 mg/ml isotonic saline. Preparations of Somatomedin A provided by KABI, of nonsuppressible insulin-like activity (NSILA) prepared by Dr. E. R. Fractionation of endogenous hormone in human plasma and of purified Som B III added to guinea pig plasma was carried out on starch gel electrophoresis (6 V/cm for 18 h). After electrophoresis, sections were cut from the gel at 1-cm intervals, frozen for 3-4 h, thawed, and eluted with 1%o control guinea pig plasma in 0.02 M barbital buffer. The gel particles were removed by centrifugation, and supernatant solutions were subjected to radioimmunoassay.
Endogenous human plasma somatomedin and labeled or unlabeled purified somatomedin added to guinea pig or human plasma were fractionated on paper electrophoresis (Whatman no. 3 paper, 0.1 M barbital buffer, pH 8.6, 6 V/ cnm for 18 h). When labeled somatomedin was employed, the strip was heat-coagulated, autoradiographed, scanned for radioactivity with a paper strip scanner, and then stained to visualize the serum proteins. When unlabeled purified or endogenous somatomedin was fractionated, the strip was cut lengthwise. One-half of the strip was heat coagulated and stained; the other half was sectioned at 1-cm intervals and eluted with standard diluent, and the eluates were subjected to radioimmunoassay.
Rough estimates of the size of endogenous human plasma somatomedin and purified Som B III added to guinea pig plasma were also obtained by ultracentrifugal analysis. Purified Som B III was added to guinea pig plasma, equilibrated for 1 h, and then diluted 1: 5. Human plasma was Turnover studies. Turnover studies in dogs were performed by administering [l'I] Somatomedin B in a pulse injection either alone or with 2-4 ml plasma from an acromegalic subj ect and which contained a high concentration of endogenous Somatomedin B activity. The labeled preparation was administered with the immunoreactive somatomedin of plasma to monitor the accuracy and reproducibility of the injection procedure. Indwelling catheters were inserted into the veins of two legs of the dog, one for injection and the other for sampling. The catheter used for sampling was maintained patent with heparin. Heparinized blood samples were taken before and at regular intervals after injection. The blood was centrifuged immediately, and the supernatant plasma was stored frozen until assayed for radioactivity or somatomedin content.
Disappearance of labeled Somatomedin B and appearance of radioiodide were analyzed by fractionation of plasma radioactivity by hydrodynamic flow chromatoelectrophoresis as well as by filtration on Sephadex G-50 columns and by measuring the total radioactivity in the plasma samples. In this way the fraction of the total radioactivity that corresponded to intact labeled hormone was monitored. Disappearance of human plasma Somatomedin B after pulse injection in a dog was determined by radioimmunoassay, and its form was determined by Sephadex gel filtration.
The rates of disappearance of labeled and unlabeled species were determined from a semilogarithmic plot of the plasma concentration as a function of time. To normalize values to become independent of the weight of the animal, tions of each were then fractionated by paper chromatoelectrophoresis, starch gel electrophoresis, and Sephadex G-50 gel filtration (Fig. 1) . The patterns obtained with all three preparations were similar on paper chromatoelectrophoresis and Sephadex gel fractionation. On starch gel the major peak of labeled Som B I was just slower than serum albumin, but for the other two preparations the major peak was immediately in advance of albumin. On Sephadex G-50 gel filtration the major fraction of labeled Somatomedin B has a peak with a partition coefficient, Kav, of about 0.6.
['I]Somatomedin B added to human or guinea pig plasma has an electrophoretic mobility on paper in the region of the a-globulins (Fig. 2) . This is in contrast to its mobility on starch gel where the same labeled preparation migrates in the prealbumin region (Fig. 1) . The electrophoretic mobility in the paper system is dependent only on charge, and in the starch gel system, because of molecular sieving, it depends on both charge and size. The greater mobility on starch gel suggests that in this system there is no evidence for binding of labeled somatomedin to guinea pig serum proteins. Using the radioimmunoassay system described in the section on Methods, the smallest measurable concentration of immunoreactive Somatomedin B is~25 pg Som B III/ml (Fig. 3) . This sensitivity permits detection of somatomedin in normal human plasma at dilutions of 1: 20,000 or greater. No detectable immunoreactive components were found in guinea pig, mouse, rat, cow, dog, sheep, pig, or rabbit plasmas at dilutions of 1: 20. Monkey plasma was assayed at a dilution of 1: 5,000.
The concentration in normal monkey plasma is about 2 Ag Som B III/ml. In 12 normal male subjects the fasting plasma somatomedin ranged from 4 to 20 ttg Som B IIII/ml with an average value of 9.8±1.5 Ag Som B III/ml. The species specificity of the assay is similar to that of the radioimmunoassay of human GH hormone, i.e., cross-reaction with primate hormone but not with that from other animal species.
[MI]Somatomedin B does not bind to antisera to insulin or GH when the antisera are used in marked (100-to 1,000-fold) ex Fig. 4 . There is some overlap between the two groups. However the mean value for untreated acromegalic subjects (19.3±2.3 Ag Som B III/ml) is about three times that of hypopituitary patients (6.6±0.5 Ag Som B III/ml). In acromegalic patients, definitive therapy (surgery or radiation) that resulted in a decrease in plasma GH concentration (Table I) also effected a reduction in the somatomedin content of plasma.
Immunoreactive Somatomedin B in unextracted human plasma elutes in the void volume on Sephadex G-50 gel filtration and in the region of [JI]--v-globulin on Sephadex G-100 and G-200 gel filtration (Fig. 5) . Prior incubation of plasma diluted 1: 10 in 7 M urea followed by fractionation on a Sephadex G-50 column equilibrated in and eluted with 7 M urea does not effect The electrophoretic mobilities on paper of endogenous human plasma Somatomedin B and of purified Som B III added to guinea pig plasma do not differ. The peak of immunoreactivity appears to be in the intra-a-globulin region (Fig. 6a) . However on starch gel electrophoresis, the major peak of endogenous human plasma somatomedin is close to the origin with some trailing up to the albumin region whereas unlabeled purified Somatomedin B added to guinea pig plasma migrates in the prealbumin region (Fig. 6b) . Thus the labeled (Figs. 1 and 2 ) and unlabeled (Fig. 6 ) purified Somatomedin B in guinea pig plasma behave indistinguishably on electrophoresis.
The similar electrophoretic mobilities on paper of endogenous plasma somatomedin and purified somatomedin do not permit decision as to whether or not purified somatomedin binds to guinea pig plasma. Starch gel electrophoresis separates on the basis of size as well as charge. Endogenous somatomedin is retarded because of its binding to a human serum protein. Purified Somatomedin B does not appear to bind to guinea pig plasma proteins and therefore migrates as a prealbumin, a mobility consistent with its charge as determined from paper electrophoresis and its size as determined by Sephadex gel filtration.
The sedimentation of endogenous Somatomedin B on ultracentrifugation is consistent with its binding to a protein approximating a-globulin in molecular weight (Fig. 7) . In contrast the major fraction of purified unlabeled Somatomedin B does not bind to guinea pig plasma since its sedimentation velocity is less than that of labeled albumin (Fig. 7) and resembles that of insulin (20) . It should be noted that the pellet in the bottom 0.5 ml contained the remaining Somatomedin B and labeled markers not found in the top nine portions shown in Fig. 7 . 1: 100 in normal saline, 90% of the Somatomedin B content is adsorbed by charcoal (10 mg/ml) within a few minutes. The Somatomedin B content of the protein fractions of human plasma prepared by the Protein Foundation, according to the Cohn ethanol scheme is given in Table  II . It must be appreciated that different laboratories may use other modifications of the Cohn procedure and these modifications may result in some differences in the extraction of Somatomedin B. The Somatomedin B concentrations in fractions III and IV were about a hundredfold higher than that in fractions II and V ('y-globulin and albumin, respectively). Dilution curves of the somatomedin contained within these protein fractions are superposable on the standard curve of Som B III (Fig. 8) . In contrast with the elution pattern observed in unextracted plasma (Fig. 5) , the Sephadex gel filtration patterns of the Cohn fractions reveal a significant and usually predominant component with an elution volume corresponding to that of the purified Som B III (Fig. 9) .
Unextracted human plasma Somatomedin B, which elutes in the void volume on Sephadex G-50 gel filtration, was administered intravenously to a dog. In postinjection samples of the dog plasma, the major component of immunoreactivity had an elution volume corresponding to that of the injected material, but there was a minor component eluting in the region of purified somatomedin (K., -0.4-0.6) (Fig. 10) fied Somatomedin B before and immediately after intravenous administration to a dog has a peak on Sephadex G-50 gel filtration with a Ka. -0.6. Subsequently, when the intact hormone has disappeared, the void volume component, corresponding presumably to the damaged labeled hormone, although initially a very minor component, appears relatively more prominent and the radioiodide generated from degraded Somatomedin B shows an absolute increase (Fig. 11) . In spite of the apparent difference in size between endogenous human Somatomedin B and radioiodinated Somatomedin B, as indicated by Sephadex gel filtration, their rates of disappearance after administration were superposable (Fig.  12) . For each form of somatomedin, the terminal portion of the disappearance curve has a half time of 50-60 min. ,.
301
DISCUSSION
The term "somatomedin" is used to designate polypeptide factors or substances in plasma that are, at least partially, GH dependent and appear to mediate the growthpromoting effect of GH in various tissues (21, 22) . The absolute degree of purity of the Somatomedin B used for labeling and as a reference substance in our radioimmunoassay is not known. However, the observation that the substance that is measured with the present assay was approximately three times higher in serum in acromegaly than in hypopituitarism and consistently fell in the former group when there was a fall in plasma GH after therapy, definitely speaks in favor of the measured substance being a GH-dependent factor and therefore a somatomedin. .. :i,
The guinea pig antiserum developed in response to immunization with human somatomedin B has a specificity directed to a factor in human and monkey plasma that was not found in plasma from many nonprimate mammalian species. The strong cross-reaction of monkey plasma in the radioimmunoassay system rules out the possibility that the antibody is directed against a plasma protein which is exclusively human. The observation that the antiserum produced in response to immunization with Somatomedin B derived from human plasma reacts only with primate plasma resembles the species specificity of antisera directed against human (h) GH. This species specificity is unique in antisera to peptide hormones and raises the question as to whether human Somatomedin B might be a fragment of hGH. Failure of Somatomedin B to react with a antiserum to hGH does not rule out this possibility, since the antiserum may not be directed toward that portion of the hGH molecule that might be somatomedin, or cleavage might so distort the configuration of the molecular fragment as to rule out the possibility for interaction with antibody to the hGH molecule. TOP BOTTOM TOP BOTTOM SUCCESSIVE 0.5-ml PORTIONS FIGURE 7 Sedimentation of endogenous Somatomedin B in human plasma, of purified Som B III added to guinea pig plasma (left) and of labeled marker molecules in human plasma (right). All plasmas were diluted 1: 5. After ultracentrifugation of 5-ml samples for 16 h in a bucket rotor (SW 50.1) at 40,000 rpm, successive 0.5-ml samples were removed for radioimmunoassay of Somatomedin B content or for assay of radioactivity content and were then compared to the mean Somatomedin B or radioactivity in uncentrifuged sample. The pellet contained in the bottom 0.5 ml balanced the reduced concentrations of immunoreactivity or radioactivity of the upper portions. Further evidence that Somatomedin B may not be directly derived from hGH is the persistance of the factor in human plasma, measurable at a dilution of 1: 10,-000 in patients in whom hGH levels in the basal state and in response to various secretagogues are below levels of detectability (< 1 ng/ml).
Other evidence that Somatomedin B may not be derived as a fragment of GH is derived from an appreciation of their relative concentrations in plasma: Somatomedin B averages about 10 itg/ml and hGH levels in normal subjects are a thousandfold lower. If the somatomedin were derived from hGH, its turnover time would have to be a thousandfold slower to maintain this steadystate concentration. Our turnover studies in the dog are consistent with a turnover time for Somatomedin B perhaps twice the 20-30-min half time for hGH in man after hypophysectomy (23) but not a thousandfold longer. However, we have not had the opportunity of measuring the disappearance of endogenous Somatomedin B in man after hypophysectomy. Because of the strong binding of endogenous Somatomedin B to human plasma proteins, the disappearance of endogenous Somatomedin B from human plasma might well be considerably slower than its disappearance from the circulation of the dog.
Generation of SF after perfusion of livers from intact rats with a nutrient medium containing bovine GH has been demonstrated (24 Consideration must be given as to whether the failure of unlabeled or labeled purified Somatomedin B to bind to serum proteins in the animal plasmas was due to alterations in structure attributable either to the initial extraction or subsequent iodination procedures. Whereas this possibility cannot be ruled out, the failure of human endogenous somatomedin, which dissociated rapidly during circulation in the dog, to rebind to dog plasma proteins cannot be accounted for by chemical alteration. The most likely explanation appears to be that the dog and guinea pig, at least, lack a specific binding protein for human Somatomedin B. However, we have also been unable to demonstrate rebinding of labeled Somatomedin B to human plasma. Whether this is due to saturation of the human binding protein and a slow rate of exchange or alteration of the labeled Somatomedin B is a problem as yet unresolved. Hintz, Orsini, and VanCamp (26) have demonstrated dissociation of somatomedin activity from a binding protein in human plasma during Sephadex gel filtration at an acid pH. The dissociated material reassociated at neutral pH with plasma proteins that had been freed of somatomedin.
The observation that the major fraction of immunoreactive Somatomedin B in Cohn fractions III and IV is in the free form could be explained in three different ways: (a) Somatomedin B was altered by the fractionations so that it could no longer bind to the binding pro- 
